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Abstract
Coexistent Brugada syndrome and Wolff-Parkinson-White (WPW) syndrome is rare, and as 
such poses management challenges. The overlap of symptoms attributable to each condition, 
the timing of ventricular stimulation after accessory pathway ablation and the predictive value 
of programmed stimulation in Brugada syndrome are controversial.  We describe a case of 
coexistent Brugada syndrome and WPW syndrome in a symptomatic young adult. We discuss 
our treatment approach and the existing literature along with the challenges in management of 
such  cases.                                    
Introduction
Both cardiac channelopathies and ventricular pre-excitation are important causes of sudden 
cardiac death in young adults. The coexistence of these conditions appears to be rare, and as 
such poses management challenges.  Advances in translational medicine between molecular 
genetics, experimental, and clinical electrophysiology have begun to shed light on the genetic 
background  of  primary  electrical  disorders.  However,  the  relationship  between  genetic 
mutations and clinical conditions are both complex and only beginning to be understood. We 
describe  a  case  of  coexistent  Brugada  syndrome  and  Wolff-Parkinson-White  (WPW) 
syndrome  in  a  symptomatic  young  adult.                                          
Case  report                                         
A 23-year-old otherwise healthy Hispanic male presented to the emergency department with 
one month of paroxysmal palpitations associated with lightheadedness and presyncope. The 
patient denied any prior true syncopal episode or any history of sudden cardiac death in his 
family.  An electrocardiogram (ECG) showed normal  sinus  rhythm with  evidence  of  right 
septal pre-excitation, incomplete right bundle branch block, and ST segment elevation in V1-
V2  consistent  with  type  1  Brugada  pattern  (Figure1).  Physical  examination  and  serum 
electrolytes were within the normal range. A chest X-ray was unremarkable. 
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Figure 1: Initial  electrocardiogram (ECG) showed normal  sinus rhythm with evidence of posteroseptal  pre-
excitation, incomplete right bundle branch block, and ST segment elevations in V1-V2.                     
Based  on  the  ECG  findings  and  the  recurrent  symptoms  the  patient  underwent 
electrophysiological study. Endocardial electrograms were bandpass filtered at 30–300 Hz and 
recorded using a computerized multichannel EP workmate 4.1 (St. Jude Medical, Inc, USA). 
Baseline conduction intervals were notable for a short HV interval of 16 milliseconds (msec).  
The  AH  interval  was  60  msec,  QRS  duration  118  msec,  and  RR  interval  1067  msec. 
Diagnostic catheters were placed via femoral access in the high right atrium (CRD, St. Jude 
Medical), His region (CRD-2, St. Jude Medical), and RV apex (CRD, St. Jude Medical),  as 
well  as  the  coronary  sinus  (Orbiter,  Bard  Electrophysiology,  USA).  During  catheter 
manipulation, pre-excited atrial fibrillation was induced with the shortest RR interval of 210 
milliseconds  (Figure  2).  The  patient  became  agitated  and  the  blood  pressure  was 
unobtainable, and the patient was successfully cardioverted with a single 50 Joule biphasic 
shock.  Atrial  extrastimulus  testing  then  induced  sustained  orthodromic  AV  reentrant 
tachycardia (AVRT) with a cycle length of 370 msec which was terminated with overdrive 
pacing (Figure 3A). A 7-French steerable, quadripolar, deflectable ablation catheter with a 4 
mm distal electrode (Biosense Webster Inc, Celsius 35E-37E, Baldwin Park, CA, U.S.A.) was 
introduced into the right atrium. Mapping using the Ensite NavXTM (St. Jude Medical) 3-
dimensional  system was  carried  out  during  atrial  pacing  to  maximize  preexcitation.  The 
earliest  ventricular  activation  was  localized  to  the  right  posterior  septum  (Figure  3B). 
Radiofrequency (RF) energy was delivered using a conventional generator (Biosense Webster 
Stockert 70 RF), with continuous monitoring of power, impedance and temperature. At the 
successful site, preexcitation terminated after 0.8 seconds of 40 watt energy delivery. There 
was no evidence of pre-excitation after an observation interval of 30 minutes. 
Figure 2: Pre-excited atrial fibrillation was induced during catheter manipulation. The shortest RR interval was 
210  milliseconds.                                                               
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Figure  3: A)  Orthodromic  AVRT was  induced  during  atrial  extrastimulus  testing.  B)  The  successful  right 
posteroseptal site shows fused atrial and ventricular signals during atrial pacing (simple arrow); termination of 
pathway conduction occurred with < 1 second RF energy, leading to widely split atrial and ventricular signals 
(split arrow). ABL- ablation catheter. HIS- His catheter, Vent-Ventricular catheter, CS Orbiter catheter with 2  
millimeter interelectrode spacing. CS Orbiter 19-20: High RA; CS Orbiter 7-8: CS Os; CS Orbiter 1-2: Distal CS  
recordings.  
Post  ablation,  the  type  1  Brugada  pattern  persisted  on  ECG  (Figure  4).  Programmed 
ventricular stimulation was carried out at the right ventricular (RV) apex and RV outflow tract  
at two different baseline drive train cycle lengths of 520 msec and 450 msec with up to triple 
extrastimuli. During ventricular stimulation of the outflow tract, VF was induced at a baseline 
drive train cycle length of 450 msec and extra stimuli of 260 msec/ 200 msec /200 msec. An 
initial attempt to cardiovert at 200 joules failed. A second shock of 300 joules converted the 
patient to sinus rhythm. 
The  following  day  an  ECG showed  a  type  2  Brugada  pattern  and  no  pre-excitation.  An 
implantable cardioverter defibrillator (ICD) was implanted after discussion with the patient. 
However, patient refused genetic testing. The patient had no siblings or children.  
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Figure  4: Type 1  Brugada  pattern  on  the  surface  electrocardiogram persisted  at  the  conclusion  of  the  AP 
ablation.
Discussion
Brugada Syndrome is  described as a clinical  condition associated with characteristic  ECG 
findings  and  an  increased  risk  of  sudden  death  due  to  ventricular  arrhythmias  [1]. 
Characteristic ECG findings include right bundle branch block and ST segment elevation in 
precordial leads V1 to V3 in the absence of electrolyte abnormalities, myocardial ischemia and 
structural  heart  disease.  Most  cases  where  a  discrete  genetic  disorder  is  identified  are 
associated with an ion channel gene mutation (SCN5A) located on chromosome 3 causing loss 
of function of the sodium channel [2]. This sodium channel blockade facilitates the loss of the 
plateau  phase  of  the  action  potential.  Because  the  right  ventricular  epicardium has  much 
higher density of transient outward current (Ito), the ventricular arrhythmia associated with 
Brugada Syndrome is right ventricular in origin [3]. An ICD is the only proven intervention in 
aborting  sudden  death  in  such  patients.  ICD  is  indicated  in  symptomatic  patients  and 
asymptomatic patients with a Type 1 pattern who develop inducible ventricular fibrillation 
during electrophysiological study, although the predictive value of EP study is controversial 
[1,4].  
The Brugada syndrome together with the WPW syndrome has been reported before in the 
medical literature [5,6]. However, in all the described cases the patients had either Brugada 
syndrome or WPW syndrome initially, and during electrophysiological study or subsequent 
follow up developed evidence of the other condition. To the best of our knowledge, this is the 
first case of simultaneous Brugada syndrome and WPW syndrome reported in the literature. 
We thought that the repolarization pattern in our patient might possibly have resulted from 
abnormal repolarization associated with AP conduction, but it remained unchanged following 
AP ablation. Reported cases have all been described in young adults. This might be explained 
due to the possibly relative high mortality of such patients who do not come to diagnosis, or to 
the tendency of some accessory pathways to lose their conduction function over time [7]. Post-
mortem studies of asymptomatic patients with WPW pattern ECG have found that in 10% of 
cases a cause of death cannot be determined [7]. One might speculate that while some of these 
patients might have been predisposed to ventricular fibrillation due to a rapidly conducting 
antegrade accessory pathway, other patients might have had unrecognized channelopathies. 
However, at this time there is no data to suggest a formal relationship between these two 
entities,  and the WPW syndrome and the Brugada syndrome are regarded as two separate 
diseases.  
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The optimal approach for sudden death prevention in these patients is unclear, and our case 
raises  a  number  of  interesting  questions.  First,  our  patient's  symptoms  might  have  been 
attributable to a tachyarrhythmia arising from either WPW or Brugada syndrome. Did our 
patient have just a Type 1 Brugada pattern ECG, or true Brugada syndrome? He had not had 
true  syncope or  observed nocturnal  apnea,  but  his  presyncopal  symptoms  were  profound. 
Secondly, how should this patient be treated and risk stratified?  EP study and ablation of a 
rapidly conducting accessory pathway is curative of WPW syndrome and the possibility of 
associated sudden death.  Programmed ventricular stimulation in a Type 1 Brugada patient is 
reasonable,  even  without  symptoms,  but  nonetheless  remains  controversial.  Finally,  it  is 
possible that the altered repolarization of the ventricular myocardium in the period after loss of 
AP conduction might have affected the inducibility  of ventricular fibrillation.  Memory T-
waves are common and may persist for weeks after ablation of manifest accessory pathways, 
reflecting this altered repolarization phenomenon [8].  In our patient we elected to perform 
ventricular  stimulation  shortly  after  AP  ablation  as  catheters  were  already  in  place.  An 
alternative strategy would have been to consider use of a wearable defibrillator for several 
weeks prior to programmed ventricular stimulation. We used a conservative approach towards 
minimizing sudden cardiac death in our young patient but the optimal strategy is uncertain.   
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